23 May 2026
The gut microbiome and osteoarthritis: what researchers are investigating
Headlines about "the gut–joint link" tend to treat the research as one thing. It isn't. It's several different kinds of study, answering different questions, with very different levels of certainty. Here's how we read it.
A quick guide to the evidence
- Mechanistic studies (cells and animals) can show a biological pathway. They can't show the same thing happens in people.
- Observational studies in people can show associations. Association isn't causation.
- Randomised trials in people can test whether a specific intervention changes an outcome.
- Product trials test a finished product. None exist for LYVA Flex.
1. People with osteoarthritis tend to have different gut bacteria
Study at a glance: Gut and joint microbiome differences in knee osteoarthritis
Study type: Systematic review of 13 studies (7 on the gut microbiome)
Who was studied: People with knee osteoarthritis compared with controls
What it found: Microbial composition differed between groups and was associated with inflammatory markers, pain and imaging findings
What it does not establish: Whether the differences cause osteoarthritis, result from it, or share another cause
Did it test LYVA Flex: No
Gilat R et al. Arthroscopy 2025;41(4):1226–1238. doi:10.1016/j.arthro.2024.05.010
2. Microbial DNA has been found in joint cartilage
Study at a glance: Microbial DNA signatures in human cartilage
Study type: Observational
Who was studied: Human knee and hip cartilage from people with and without osteoarthritis
What it found: Cartilage from people with osteoarthritis carried a different pattern of microbial DNA
What it does not establish: It detected DNA, not living bacteria, and shows an association rather than a cause
Did it test LYVA Flex: No
Dunn CM et al. Arthritis & Rheumatology 2020;72(7):1111–1122. doi:10.1002/art.41210
3. A gut-to-cartilage pathway has been mapped in mice
Study at a glance: Bile acids, GLP-1 and knee osteoarthritis
Study type: Human observational data plus mouse experiments
Who was studied: Over 1,800 people for blood metabolites, 981 for stool samples, and mouse models
What it found: Lower levels of a gut-related bile acid were associated with knee osteoarthritis. In mice, a pathway from the gut through the hormone GLP-1 altered cartilage outcomes in the mouse model
What it does not establish: That the pathway works the same way in people, or that diet or supplements can change it
Did it test LYVA Flex: No
Yang Y et al. Science 2025;388:eadt0548. doi:10.1126/science.adt0548
4. In obese mice, a prebiotic changed the picture
Study at a glance: The gut microbiome and the osteoarthritis of obesity
Study type: Animal study
Who was studied: Mice fed a high-fat diet
What it found: Obesity-related joint damage was linked to systemic inflammation, and a prebiotic fibre (oligofructose) shifted the gut microbiome towards a lean-type profile
What it does not establish: Anything directly about people
Did it test LYVA Flex: No
Schott EM et al. JCI Insight 2018;3(8):e95997. doi:10.1172/jci.insight.95997
5. Short-chain fatty acids are a proposed link
Study at a glance: Short-chain fatty acids and the gut–joint axis
Study type: Narrative review
Who was studied: Summarises mostly laboratory and animal research
What it found: Proposes that short-chain fatty acids — produced when gut bacteria ferment fibre — may influence the gut barrier, cartilage and the bone beneath it
What it does not establish: A review adds no new data, and most of the evidence it draws on is preclinical
Did it test LYVA Flex: No
Han J et al. Stem Cell Research & Therapy 2025;16:251. doi:10.1186/s13287-025-04386-3
6. One small human trial of prebiotic fibre
Study at a glance: Prebiotic fibre and physical function
Study type: Randomised controlled trial
Who was studied: 54 adults, mostly women, with knee osteoarthritis and obesity, over 6 months
What it found: Compared with placebo, the fibre group improved on several physical function tests. The change in knee pain was not statistically significant. The authors called for larger trials
What it does not establish: It's small and in a specific population. It is relevant to the research area, but it is not a trial of LYVA Flex
Did it test LYVA Flex: No
Fortuna R et al. European Journal of Nutrition 2024;63(6):2149–2161. doi:10.1007/s00394-024-03415-w
Putting it together
Taken together, this is a field worth following: associations reported in human studies, plausible mechanisms explored in animals, and early human intervention research. A 2026 review in Nature Reviews Rheumatology called it an "emerging concept" — and noted that evidence for treatments targeting it "remains limited".
What it isn't, yet, is proof that changing the gut changes joints. Anyone who tells you otherwise is running ahead of the science.
Where LYVA stands
We're developing LYVA Flex with this research in mind — starting further upstream, with the gut environment as well as the joint. It's a food supplement for healthy movement, not a treatment for osteoarthritis, and it hasn't been tested in a clinical trial. When the evidence moves, we'll tell you.
Explore how we are developing LYVA Flex: read the science or join the waitlist.
This article is for general information only. It is not medical advice. LYVA Flex is a food supplement, not a medicine. If you have a joint condition or take medication, speak to your GP or physiotherapist.
— William Tyler-Street, Founder